Topical treatment of actinic keratoses with potassium dobesilate 5% cream. a preliminary open-label study.

Abstract

BACKGROUND:

Fibroblast growth factor (FGF) is involved in skin tumorigenesis: it promotes cell viability, induces angiogenesis and stimulates invasiveness. Dobesilate is a drug that blocks the activity of FGF. The primary objective was to evaluate the efficacy and tolerability of potassium dobesilate 5% cream in the treatment of actinic keratoses.

METHODS:

Potassium dobesilate 5% cream was applied twice daily for 16 weeks to actinic keratosis lesions in 30 patients. The lesions were evaluated clinically at an initial baseline visit, at intermediate visits, and at 16 weeks of treatment.

RESULTS:

The use of potassium dobesilate 5% cream for 16 weeks induced complete regression in 70% of evaluated actinic keratoses, corresponding to grade I, II and III clinical variants, and a partial response (at least 75% reduction of lesions) in 20% of the cases.

CONCLUSION:

Our preliminary trial shows that potassium dobesilate exerts anti-tumorigenic effects and may play a useful role in the chemoprevention of skin cancers.

• Authors: Pedro Cuevas Sánchez, W Espinoza, C Pérez, J Angulo, G Giménez-Gallego
• Journal: European journal of medical research (Eur J Med Res) Vol. 16 Issue 2 Pg. 67-70 (Feb 24 2011) ISSN: 0949-2321 [Print] England
• PMID: 21463984 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anticarcinogenic Agents
• Benzenesulfonates
• Dermatologic Agents
• potassium dobesilate

Topics

• Administration, Cutaneous
• Aged
• Aged, 80 and over
• Anticarcinogenic Agents (therapeutic use)
• Benzenesulfonates (therapeutic use)
• Dermatologic Agents (therapeutic use)
• Female
• Humans
• Keratosis, Actinic (drug therapy)
• Male
• Middle Aged
• Skin Neoplasms (drug therapy)
• Sunlight
• Treatment Outcome